印度儿童中针对5型腺病毒的中和抗体血清流行率：对基于重组腺病毒的疫苗的影响。
Seroprevalence of neutralizing antibodies to adenovirus type 5 among children in India: implications for recombinant adenovirus-based vaccines.
作者信息
Appaiahgari Mohan Babu, Pandey Ravindra Mohan, Vrati Sudhanshu
机构信息
National Institute of Immunology, Aruna saf Ali Marg, JNU Complex, New Delhi 110067, India.
出版信息
Clin Vaccine Immunol. 2007 Aug;14(8):1053-5. doi: 10.1128/CVI.00173-07. Epub 2007 Jun 27.
Abstract
We determined the levels of adenovirus 5 (Ad5) neutralizing antibodies in children in India less than 2 years of age. The results clearly show an age-dependent increase in Ad5-specific immunity, with 7- to 12-month-old children having the lowest levels of Ad5 immunity. This opens up the scope for the use of recombinant Ad5-based vaccines in this age group.
摘要
我们测定了印度2岁以下儿童体内腺病毒5型（Ad5）中和抗体的水平。结果清楚地显示，Ad5特异性免疫力随年龄增长而增加，7至12个月大的儿童Ad5免疫力水平最低。这为在该年龄组使用基于重组Ad5的疫苗开辟了空间。
相似文献
1
Seroprevalence of neutralizing antibodies to adenovirus type 5 among children in India: implications for recombinant adenovirus-based vaccines.
Clin Vaccine Immunol. 2007 Aug;14(8):1053-5. doi: 10.1128/CVI.00173-07. Epub 2007 Jun 27.
2
International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials.
Vaccine. 2010 Jan 22;28(4):950-7. doi: 10.1016/j.vaccine.2009.10.145. Epub 2009 Nov 17.
3
Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors.
J Virol. 2004 Mar;78(6):2666-73. doi: 10.1128/jvi.78.6.2666-2673.2004.
4
[Frequency of adenovirus group complement-specific antibodies in children].
Mikrobiyol Bul. 1990 Jan;24(1):16-9.
5
The prevalence of antibodies to adenovirus serotype 5 in an adult Indian population and implications for adenovirus vector vaccines.
J Med Virol. 2010 Mar;82(3):407-14. doi: 10.1002/jmv.21721.
6
Emergence of adenovirus type 14 in US military recruits--a new challenge.
J Infect Dis. 2007 Nov 15;196(10):1436-7. doi: 10.1086/522969. Epub 2007 Oct 31.
7
Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa.
J Clin Microbiol. 2006 Oct;44(10):3781-3. doi: 10.1128/JCM.01249-06.
8
A serological survey of human adenovirus serotype 2 and 5 circulating pediatric populations in Changchun, China, 2011.
Virol J. 2012 Nov 23;9:287. doi: 10.1186/1743-422X-9-287.
9
Designed recombinant adenovirus type 5 vector induced envelope-specific CD8(+) cytotoxic T lymphocytes and cross-reactive neutralizing antibodies against human immunodeficiency virus type 1.
J Gene Med. 2009 Feb;11(2):139-49. doi: 10.1002/jgm.1277.
10
Prevalence of serum neutralizing antibodies to adenovirus type 5 (Ad5) and 41 (Ad41) in children is associated with age and sanitary conditions.
Vaccine. 2016 Nov 4;34(46):5579-5586. doi: 10.1016/j.vaccine.2016.09.043.
引用本文的文献
1
Global Prevalence of Preexisting Antibodies against Human Adenoviruses, Surveyed from 1962 to 2021.
Intervirology. 2024;67(1):19-39. doi: 10.1159/000538233. Epub 2024 Mar 8.
2
Oligopeptide-modified poly(beta-amino ester)s-coated AdNuPARmE1A: Boosting the efficacy of intravenously administered therapeutic adenoviruses.
Theranostics. 2020 Feb 3;10(6):2744-2758. doi: 10.7150/thno.40902. eCollection 2020.
3
Seroprevalence of Neutralizing Antibodies against Human Adenovirus Type-5 and Chimpanzee Adenovirus Type-68 in Cancer Patients.
Front Immunol. 2018 Mar 7;9:335. doi: 10.3389/fimmu.2018.00335. eCollection 2018.
4
Vaccines against Botulism.
Toxins (Basel). 2017 Sep 2;9(9):268. doi: 10.3390/toxins9090268.
5
Novel vaccination approaches to prevent tuberculosis in children.
Pneumonia (Nathan). 2016 Nov 24;8:18. doi: 10.1186/s41479-016-0020-z. eCollection 2016.
6
Neutralizing antibodies against adenovirus type 2 in normal and HIV-1-infected subjects: Implications for use of Ad2 vectors in vaccines.
Hum Vaccin Immunother. 2017 Jun 3;13(6):1-8. doi: 10.1080/21645515.2017.1281487. Epub 2017 Mar 16.
7
Prevalence of serum neutralizing antibodies to adenovirus type 5 (Ad5) and 41 (Ad41) in children is associated with age and sanitary conditions.
Vaccine. 2016 Nov 4;34(46):5579-5586. doi: 10.1016/j.vaccine.2016.09.043.
8
Vaccination with Replication Deficient Adenovectors Encoding YF-17D Antigens Induces Long-Lasting Protection from Severe Yellow Fever Virus Infection in Mice.
PLoS Negl Trop Dis. 2016 Feb 17;10(2):e0004464. doi: 10.1371/journal.pntd.0004464. eCollection 2016 Feb.
9
Adenovirus Specific Pre-Immunity Induced by Natural Route of Infection Does Not Impair Transduction by Adenoviral Vaccine Vectors in Mice.
PLoS One. 2015 Dec 17;10(12):e0145260. doi: 10.1371/journal.pone.0145260. eCollection 2015.
10
Low seroprevalent species D adenovirus vectors as influenza vaccines.
PLoS One. 2013 Aug 22;8(8):e73313. doi: 10.1371/journal.pone.0073313. eCollection 2013.
本文引用的文献
1
Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa.
J Clin Microbiol. 2006 Oct;44(10):3781-3. doi: 10.1128/JCM.01249-06.
2
An adenovirus-based HIV subtype B prime/boost vaccine regimen elicits antibodies mediating broad antibody-dependent cellular cytotoxicity against non-subtype B HIV strains.
J Acquir Immune Defic Syndr. 2006 Nov 1;43(3):270-7. doi: 10.1097/01.qai.0000230318.40170.60.
3
Intracoronary delivery of an adenovirus encoding fibroblast growth factor-4 in myocardial ischemia: effect of serum antibodies and previous exposure to adenovirus.
Hum Gene Ther. 2006 Feb;17(2):230-8. doi: 10.1089/hum.2006.17.230.
4
Broad cellular immunity with robust memory responses to simian immunodeficiency virus following serial vaccination with adenovirus 5- and 35-based vectors.
J Gen Virol. 2006 Jan;87(Pt 1):139-149. doi: 10.1099/vir.0.81445-0.
5
Detection of antibodies against adenovirus protein IX, fiber, and hexon in human sera by immunoblot assay.
J Clin Microbiol. 2005 Sep;43(9):4426-33. doi: 10.1128/JCM.43.9.4426-4433.2005.
6
Immunization with recombinant adenovirus synthesizing the secretory form of Japanese encephalitis virus envelope protein protects adenovirus-exposed mice against lethal encephalitis.
Microbes Infect. 2006 Jan;8(1):92-104. doi: 10.1016/j.micinf.2005.05.023. Epub 2005 Aug 9.
7
Tumor cell targeted gene delivery by adenovirus 5 vectors carrying knobless fibers with antibody-binding domains.
Gene Ther. 2005 Feb;12(3):211-24. doi: 10.1038/sj.gt.3302408.
8
Gene transduction and cell entry pathway of fiber-modified adenovirus type 5 vectors carrying novel endocytic peptide ligands selected on human tracheal glandular cells.
J Virol. 2004 Jul;78(13):7227-47. doi: 10.1128/JVI.78.13.7227-7247.2004.
9
An adenovirus vector with a chimeric fiber derived from canine adenovirus type 2 displays novel tropism.
Virology. 2004 Jun 20;324(1):103-16. doi: 10.1016/j.virol.2004.03.028.
10
Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector.
AIDS. 2004 May 21;18(8):1213-6. doi: 10.1097/00002030-200405210-00019.
Zotero 插件